I haven't yet seen any statistics on GVAX plus/minus Taxotere in randomized trials. Even with Provenge, the later Taxotere patients are merely a self-selected subgroup. So right now, it's only an interesting theory, albeit with much potential.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.